Please join us on May 19, 2021 at 1:00 pm ET as Molly Simpson, Marketing Director, of Apollo Intelligence—parent company of InCrowd—present Oncology Biomarker Testing—Awareness, Drivers, and the Future.

The field of oncology biomarker testing is growing rapidly. With so many new cancer treatments available requiring specific biomarkers for prescription, oncologists have plenty of new information to follow and many decisions to make when treating individual tumors.

Key learnings:

  • Thoughts on how oncologists learn about new biomarker tests
  • Views on what other education resources would be helpful
  • Perspectives on oncology biomarker test choice and how these decisions are made
  • Trends and changes in the kinds of tests being conducted, especially around tissue vs liquid testing in solid tumors

Featured Speakers

Molly Simpson

Marketing Director
InCrowd

Molly Simpson is the Apollo Intelligence Marketing Director for InCrowd. She joined the Apollo Marketing team after several years in Sales and Client Service at InCrowd. Molly started at InCrowd with a diverse background in client services and marketing research. Molly has worked in a variety of industries in this regard including healthcare, consumer product goods, banking, and publishing. Molly has studied and traveled abroad in Europe, Central America, and the Middle East. She holds a bachelor’s degree from Northeastern University.

Meghan Oates-Zalesky

Senior Vice President of Marketing
Apollo Intelligence

Meghan Oates-Zalesky, Senior Vice President of Marketing for Apollo Intelligence, LLC, is responsible for leading marketing strategy for Apollo, InCrowd, and SurveyHealthcareGlobus brands. Meg has 20 years of marketing and business strategy experience, with the majority of her career spent in healthcare technology and life sciences. She is a published author and contributor to PharmaExec, PM360, and the Huffington Post, among other outlets.

NOW AVAILABLE ON-DEMAND

Register now